Protein kinase inhibitors.

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Protein kinases play crucial roles in cellular processes.
• Dysregulation of protein kinases is implicated in numerous diseases, particularly malignancies.
• Protein kinases are recognized as significant therapeutic targets for disease intervention.

Purpose of the Study:

• To review the development and therapeutic potential of protein kinase inhibitors.
• To highlight the significance of targeting protein kinases in medicine, especially in oncology.

Main Methods:

• Review of existing literature on protein kinase inhibitors.
• Analysis of small molecule inhibitors targeting the ATP-binding site of protein kinases.
• Examples of clinically approved and investigational kinase inhibitors.

Main Results:

• Numerous low molecular weight protein kinase inhibitors have been designed.
• Many inhibitors compete with ATP for the ATP-binding site.
• Several inhibitors, such as imatinib mesylate, flavopiridol, roscovitine, erlotinib, and gefitinib, are in clinical trials or approved treatments.

Conclusions:

• Targeting protein kinases represents a promising therapeutic strategy.
• The discovery of protein kinase inhibitors heralds a new era in medicine, particularly in non-invasive cancer treatment.
• Protein kinase inhibitors offer new hope for effective cancer therapies.